Compare · GLP-1 agonist
Retatrutide vs VK2735
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Retatrutide | VK2735 | |
|---|---|---|
| Evidence | 7/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. | VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown. |
| Full profile → | Full profile → |
Retatrutide
Retatrutide (Lilly's lab code LY3437943) is an experimental injectable drug being studied for obesity and type 2 diabetes. It has shown some of the biggest weight-loss numbers seen in any trial so far. But as of June 2026 it is not approved anywhere, and the big Phase 3 results that matter most…
VK2735
VK2735 is an experimental obesity drug from a company called Viking Therapeutics. It's part of the incretin family (a group of gut-hormone-based drugs that turn down appetite) — the same broad family as semaglutide and tirzepatide. It has drawn a lot of buzz for two reasons: its early results in…